ImmunityBio, Inc. IBRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$632.8M-921% | -$61.96M+7.9% | -$67.27M+27.3% | -$92.57M+28.6% | -$129.67M-119% | ||
| $4.38M+13.3% | $3.87M-2.2% | $3.95M+1.8% | $3.88M+1.3% | $3.83M-7.5% | ||
| $8.17M-6.6% | $8.75M-1.5% | $8.88M-8.0% | $9.65M+1.2% | $9.54M+5.5% | ||
| $700K-93.4% | $10.56M+6.7% | $9.89M+94.0% | $5.1M-65.3% | $14.67M— | ||
| $4.99M-36.9% | $7.89M+12,430% | $63K+103% | -$1.8M-1,149% | $172K-97.3% | ||
| $3.9M— | —— | -$1.39M— | —— | $6.44M+300% | ||
| $3.14M+63.0% | $1.93M-64.8% | $5.47M-37.3% | $8.72M+167% | -$12.93M-512% | ||
| $1.05M— | —— | —— | -$1.23M-1,561% | $84K-91.9% | ||
| $16K-80.5% | $82K+134% | $35K-83.3% | $210K-13.6% | $243K— | ||
| -$180K-543% | -$28K-165% | $43K+1,175% | -$4K+63.6% | -$11K+98.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $4M— | —— | ||
| -$75.36M-7.1% | -$70.38M-2.1% | -$68.91M+13.6% | -$79.75M+7.2% | -$85.91M-0.9% | ||
| $1.78M+96.7% | $903K+21.9% | $741K-31.5% | $1.08M-3.6% | $1.12M-46.9% | ||
| $139.09M+205% | $45.63M-74.7% | $180.59M+1,099% | $15.06M+14,961% | $100K-98.4% | ||
| $79.38M+33.3% | $59.55M— | —— | —— | $5.35M-70.3% | ||
| -$31.65M— | —— | -$181.36M-1,024% | -$16.14M-491% | $4.13M— | ||
| $61K— | —— | —— | —— | $0— | ||
| $868K— | —— | —— | —— | $0— | ||
| $971K-39.8% | $1.61M— | —— | —— | $220K-90.2% | ||
| $13K+8.3% | $12K0.0% | $12K+200% | $4K— | $0— | ||
| $6.99M+1,085% | $590K+291% | $151K-53.1% | $322K-73.2% | $1.2M+49.7% | ||
| $223.93M+308% | $54.89M-68.4% | $173.52M+0.4% | $172.81M+17,698% | -$982K-101% | ||
| $122K+2,340% | $5K— | —— | $76K+860% | -$10K-42.9% | ||
| $117.04M— | —— | -$76.81M— | —— | -$82.77M— | ||
| $20.12M+8.2% | $18.59M+1.7% | $18.27M-3.1% | $18.87M+21.0% | $15.59M-25.3% | ||
| $1.53M-10.4% | $1.7M+74.2% | $978K+8,791% | $11K-78.8% | $52K+117% | ||
| -$1.11M— | —— | -$289K+85.0% | -$1.93M+65.4% | -$5.58M— | ||
| $3.9M— | —— | -$1.39M— | —— | $6.44M+300% | ||
| $570K— | —— | $501K— | —— | $51K-77.1% | ||
| $3.14M+63.0% | $1.93M-64.8% | $5.47M-37.3% | $8.72M+167% | -$12.93M-512% | ||
| $8.32M-3.7% | $8.63M-7.3% | $9.31M-7.1% | $10.02M-24.5% | $13.27M+28.9% | ||
| $62K-1.6% | $63K0.0% | $63K+1.6% | $62K0.0% | $62K+105% | ||
| $1.43M— | —— | —— | —— | $0— | ||
| —— | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M— | ||
| $7.44M— | —— | —— | —— | $0— | ||
| $10M— | $0— | —— | —— | $0-100% | ||
| $11K-97.0% | $372K— | —— | —— | $0— | ||
| $79.38M+33.3% | $59.55M— | —— | —— | $5.35M-70.3% | ||
| $13K+8.3% | $12K0.0% | $12K+200% | $4K— | $0— | ||
| $102.23M— | —— | —— | —— | $0— | ||
| $61K— | —— | —— | —— | $0— | ||
| $53.54M— | $0— | $0— | $0— | $0— | ||
| $868K— | —— | —— | —— | $0— | ||
| $1.41M+77.5% | $792K— | —— | $197K-82.2% | $1.11M— | ||
| —— | $0— | $0— | $0— | $0— | ||
| $54K— | —— | —— | —— | $0— | ||
| $122K+2,340% | $5K— | —— | $76K+860% | -$10K-42.9% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $295.41M+1,061% | -$30.74M-106% | -$14.91M-283% | -$3.89M-968% | $448K+105% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $75M— | $0— | $0— | $0— | $0-100% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $1.72M+25.0% | $1.38M— | $0-100% | $4.53M— | $0— | ||
| $16.38M+916% | $1.61M— | —— | —— | $3M+33.5% | ||
| $136K+109% | $65K-40.9% | $110K-6.8% | $118K— | $0-100% | ||
| -$180K— | —— | $43K+1,175% | -$4K+63.6% | -$11K— | ||
| $35.33M— | —— | —— | —— | $0— | ||
| -$77.14M-8.2% | -$71.28M-2.3% | -$69.65M+13.8% | -$80.83M+7.1% | -$87.03M+0.3% | ||
| -$77.14M-8.2% | -$71.28M-2.3% | -$69.65M+13.8% | -$80.83M+7.1% | -$87.03M+0.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
